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Abstract
The transcriptional activator TAT is a small peptide essential for viral replication and possesses the property of entering the cells from
the extracellular milieu, acting as a membrane shuttle. In order to safely differentiate cells an innovative methodology, based on the
fusion of transcription factors and the TAT sequence, is discussed in this short review. In several studies, it has been demonstrated that
TAT protein can be observed in the cell nucleus after few hours from the inoculation although its way of action is not fully understood.
However, further studies will be necessary to develop this methodology for clinical purposes.
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The HIV-1 trans-activator gene (TAT) is essential for the latent transcription of the HIV virus, for its replication and for its gene
expression.  In addition, the TAT protein is able to conjugate with exogenous molecules (like nucleic acids, protein, peptides or drug
molecules) mediating their delivery into the cell through the plasma membrane or the nucleus through the nuclear membrane.  As a
matter of fact, the TAT protein belongs to the protein transduction domain (PTD) family. Its ability to fuse and deliver recombinant
proteins, as well as therapeutic ones, has been studied in different fields (e.g. disease treatment and diagnosis), especially in the research
for the cancer treatment.  The HIV TAT protein transduction motif along with the Drosophila antennapeptide (Antp) and the herpes
simplex virus VP22 protein, are generally the most studied PTDs. They differ in their length and amino acid sequence but they share the
same “cell-penetrating effect”.  There are several reasons why PTDs are widely used: they transport macromolecules into cells, they
have almost no cytotoxicity and most importantly they usually do not modify the genome of the target cells. These characteristics give
the PTDs an excellent biological safety; its transduction ability and characteristics appear interesting to induce tissue-specific
differentiation when the TAT protein is associated to transcription factors, e.g. in the myogenic differentiation,  or in reprogramming
adult stem cells.
The purpose of this short review was to summarize the principal characteristics of TAT and its role in the differentiation or
reprogramming when conjugated to particular proteins.
Structure, functional domain and mechanism of uptake
The HIV-1 TAT protein is 86 amino acids long and consists of two exons: the first one of 72 amino acids and the second of 14.
According to its amino acidic sequence this protein can be divided into different domains, the most important one is the core domain (aa
47-57)  in which relies the transducing ability of the TAT protein. The amino acidic composition of the core domain is fundamental to
carry out the transduction of the cargo into target cells. Some studies have shown that to enable an efficient transmembrane movement
this domain must be rich in basic amino acids (like arginine or lysine). In fact, an enrichment in positively charged amino acids
enhances its function.  This led researchers to improve the efficiency of the transduction of TAT by modifying its sequence adding
basic amino acids or by modification of its structure.  Indeed, it has been demonstrated that short peptides rich in arginine are rapidly
internalized by cells, in a receptor-independent manner;  therefore, it was suggested that the process of TAT internalization occurs
through adsorptive endocytosis. This does not happen for TAT basic domain when fused to protein cargos.
TAT usage for iPSCs generation
Induced pluripotent stem cells (iPSCs)  might be a useful tool for disease modeling as well as in regenerative medicine. However,
before the clinical application of this method, the safety and efficiency must be completely assessed. At first, in order to generate iPSCs,
the reprogramming procedure was accomplished with genome-integrating retroviruses but this may lead to an unwanted genetic
dysfunction (e.g. mutagenesis) and this is unlikely to be accepted in a clinical scenario.  As a result, more virus-free strategies were
developed to overcome the genetic manipulation: Sendai virus,  episomal vectors  or plasmids.  Albeit a reduction in the genome
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integration was observed by these approaches, the DNA excised from the vectors can lead to transgene insertion. Consequently, a
technique which does not involve the usage of nucleic acid was desirable. The delivery of recombinant proteins using PTDs is a possible
way to overcome the issue of the DNA mutagenesis and it seems to be the most suitable and effective one.  This delivery method
guarantees no genomic integration but on the other hand it shows a relatively lower efficiency than the previous methods. Therefore, it
was necessary to study methods, like the small chemical molecules, that can support the protein-based iPSCs generation order to
improve its limited reprogramming ability, e.g. Valproic acid (VPA).  Zhou et al. (2009)  showed for the first time the generation of
mouse iPSCs using a 11 arginine (R)-tagged recombinant protein combined with the histone deacetylase (HDAC) inhibitor VPA. A
successful generation of iPSCs in human newborn fibroblast was obtained by Kim et al. (2009)  using a 9-arginine (9R) fused to the
reprogramming factors (RF) Oct-4, Sox-2, Klf4 and c-Myc. In a later study, Zhang et al. (2012)  compared the latter delivery approach
and TAT-recombinant protein in iPSCs reprogramming in human foreskin fibroblasts. Their outcomes showed that RF fused with TAT
resulted in a higher transcriptional activity.
TAT-MyoD fused protein: an example of TAT application in an in vitro differentiation protocol
MyoD is a transcription factor that plays a key role in the muscular differentiation.  In addition, Hidema et al. (2012)  showed that
MyoD protein fused with TAT has a higher differentiating potential than the wild type MyoD. Recently, the potential of the complex
TAT-MyoD in inducing equine peripheral blood mesenchymal stem cells (PB-MSCs) towards the myogenic fate has been evaluated.
Mesenchymal stem cells are an undifferentiated multipotent cell population which deserves a particular attention because they offer an
alternative therapeutic solution for muscle diseases.  Up to now, scarce data were present in literature about the differentiation of MSCs
into myoblasts, but in vitro it has been shown that MSCs may differentiate into skeletal muscle cells with conditioned medium as well as
in co-colture with a fusion between MSCs and myoblasts.  Although data indicate that TAT-MyoD induces myogenic differentiation
in naturally predisposed cells only, like the C2C12 cell line  or the mouse muscle primary cells,  some authors demonstrated that the
efficiency of myogenic differentiation with Tat-MyoD transduction of human adipose-derived stem cells was reached only when it was
fused with C2C12 myoblasts.  Our research group has shown that the supplement of TAT-MyoD alone was not sufficient to induce
cellular differentiation, even if it activated the myogenic pathway at the nuclear level. Therefore, in order to achieve the myogenic
differentiation of MSCs, conditioned medium was added. This creates a suitable in vitro microenvironment for the differentiation
towards muscle cells. These results suggest that TAT-mediated protein transduction system, if supported by a conditioned medium,
might represents a useful methodology to induce myoblasts differentiation. Moreover, this indicates that the development of myogenic
phenotypes of mesenchymal stem cells by TAT-MyoD construct depends on time and culture conditions, highlighting the essential role
of the in vitro microenvironment in terms of secreted factors and cell contacts; other studies confirmed the necessity to have other
factors apart from the genetic ones (i.e. MyoD) to commit undifferentiated cells.  The advantage of having a robust myogenic
differentiation method by means of the TAT-mediated protein transduction consists in obtaining committed myogenic cells derived from
an abundant cell source, like the peripheral blood, without the need to fuse them with other cells. Certainly, this innovative approach of
protein transduction with TAT fused with various transcription factors appears extremely interesting in the therapeutic and regenerative
medicine field.
Limitations and possible solutions
Even though progress has been made on TAT transduction ability for research purposes there are still some intriguing issues, e.g. slow
endosomal release. In fact, if the TAT-recombinant protein complex is packaged for too long in the endosomes it could be degraded or
refolded.  However, scientists tried to overcome this problem with the use of chemical auxiliary like Ca  or sucrose,  the use of
radiation after labeling the TAT protein with photosensitive agents  or the modification of its amino acidic sequence as previously
stated. Another concern about the usage of TAT is the quality and the production of the recombinant protein to which TAT is fused. Even
if these proteins are usually produced in a highly efficient way with bacterial expression vectors  the real issues are the consequential
steps of purification that may affect the biological activity of the protein.  The expression in the mammalian cells might be an
alternative to the bacterial expression system, in order to have proper post-translational modifications such as a correct folding of the
protein.  In the future, the research should focus on the study of the mechanism of internalization because it is still unclear although the
internalization by macropinocytosis it is the most validated hypothesis.  Identifying new small chemical compounds that can enhance
the transduction is another goal due to its low efficiency in reprogramming target cells. Moreover, its application in in vivo study should
be more investigated. First of all, it would be necessary to produce an amount of secreted protein sufficient for large-scale studies. Then
it should be performed a research about its possible toxicity in vivo. Although it has been widely demonstrated that the HIV-1 TAT
protein can deliver many molecules like peptides, proteins, drug molecules or nucleic acids more in vivo studies are mandatory. In
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conclusion, thanks to recent experiments it has been also assessed that it has an excellent biological safety; these characteristics, plus the
absence of modification of the genetic code, make this method a suitable tool for different fields of study such as pharmacology, disease
treatment and direct lineage reprogramming for regenerative purposes.
Combined with recent advancements in skeletal muscle clinical modulation and regeneration,  the described innovative methodology
based on the fusion of transcription factors and the TAT sequence, may open new options for patients in need of skeletal muscle
reconstruction.
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